Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024
SOUTH SAN FRANCISCO, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) — Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it will host an investor webcast to highlight the broad opportunity for its foundational ADC program, Luveltamab tazevibulin (luvelta), a novel folate receptor-α (FolRα) targeting ADC which has now shown clinical activity in three different tumor types to date. The live webcast will be held on Thursday, January 4, 2024, starting at 1:30 p.m. PT / 4:30 p.m. ET featuring presentations by members of Sutro’s senior management team and external key opinion leaders in oncology; and concluding with a Q&A session.
Related news for (STRO)
- Sutro Biopharma Appoints Greg Chow as Chief Financial Officer
- Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights
- MoBot’s Stock Market Highlights – 04/30/25 06:00 PM
- MoBot’s Stock Market Highlights – 04/30/25 05:00 PM
- Don’t Miss Out: MoBot’s Latest Stock Updates 04/30/25 04:00 PM